Ann-Lii Cheng
Taiwanese oncologist who led the Asia-Pacific sorafenib trial and co-led IMbrave150, the immunotherapy standard for liver cancer.
Overview
Ann-Lii Cheng led the Asia-Pacific trial that confirmed sorafenib's benefit in hepatitis B-driven hepatocellular carcinoma and was co-principal investigator of IMbrave150, which established atezolizumab plus bevacizumab as first-line therapy. He has led or co-led most major HCC systemic therapy trials in Asia, including REFLECT (lenvatinib) and the adjuvant IMbrave050 study.
Pages like this
not linked directly; found by shared links- PersonRichard S. Finn
Shares IMbrave150, IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer, Atezolizumab, PD-L1 and the tag hcc.
- PersonHo Yeong Lim
Shares IMbrave150, IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer, Atezolizumab, Hepatocellular carcinoma.
- PersonMasatoshi Kudo
Shares REFLECT, Hepatocellular carcinoma and the tag hcc.
- PersonArjun V. Balar
Shares Atezolizumab, PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonJonathan E. Rosenberg
Shares Atezolizumab, PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.
- PersonPeter Schmid
Shares Atezolizumab, PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.
- PairingCaution: bevacizumab-based regimens with untreated varices
Shares IMbrave150, Atezolizumab, Hepatocellular carcinoma.
- PersonGordon J. Freeman
Shares PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.